22.418 articles found

ORALLY BIOAVAILABLE PRODUCTS OF (+)-3-HYDROXYMORPHINAN FOR PARKINSON'S DISEASE PREVENTION OR TREATMENT

LEE JINHWA, KIM JEONGMIN, JUNG MYUNG EUN, KIM JONG YUP, SONG KWANG-SEOP, SON EUN JUNG, LEE SUK HO, HAN HO KYUN, KIM MIN JU, LEE MINWOO.

· 2008-03-07

Orally bioavailable prodrugs of (+)-3-hydroxymorphinan for parkinson's disease prevention or treatment

JEONGMIN KIM, JINHWA LEE, HO LEE SUK, YUP KIM JONG, MINWOO LEE, KWANG-SEOP SONG, JUNG SON EUN, JU KIM MIN, KYUN HAN HO, EUN JUNG MYUNG.

· 2008-03-07

ORALLY BIOAVAILABLE PRODRUGS OF (+)-3-HYDROXYMORPHINAN FOR PARKINSON'S DISEASE PREVENTION OR TREATMENT

LEE JIN HWA, KIM JEONG MIN, JUNG MYUNG EUN, KIM JONG YUP, SONG KWANG SEOP, SON EUN JUNG, LEE SUK HO, HAN HO KYUN, KIM MIN JU, LEE MIN WOO.

· 2008-03-07

Orally bioavailable prodrugs of (+)-3-hydroxymorphinan for Parkinson's disease prevention or treatment

KIM JEONGMIN, LEE JINHWA, LEE SUK HO, KIM JONG YUP, LEE MINWOO, SONG KWANG-SEOP, SON EUN JUNG, KIM MIN JU, HAN HO KYUN, JUNG MYUNG EUN.

· 2008-03-07

ORALLY BIOAVAILABLE PRODRUGS OF (+)-3-HYDROXYMORPHINAN FOR PARKINSON'S DISEASE PREVENTION OR TREATMENT

SON EUN JUNG, KIM JEONGMIN, JUNG MYUNG EUN, KIM JONG YUP, SONG KWANG-SEOP, PARK JI-HYUN, LEE JINHWA, LEE MINWOO, LEE SUK HO, KIM MIN-AH, HAN HO KYUN.

· 2008-03-07

Potential applications of nanotechnologies to Parkinson's disease therapy.

Linazasoro G, Nanotechnologies for Neurodegenerative Diseases Study Group of the Basque Country (NANEDIS).

Parkinsonism Relat Disord · 2008-03-07

DOI: 10.1016/j.parkreldis.2007.11.012PMID: 18329315

Therapeutic role of sirtuins in neurodegenerative disease.

Outeiro TF, Marques O, Kazantsev A.

Biochim Biophys Acta · 2008-03-07

DOI: 10.1016/j.bbadis.2008.02.010PMID: 18373985

Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.

Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, Pacchetti C, Zibetti M, Natuzzi F, Lopiano L, Nappi G, Pezzoli G.

Neurodegener Dis · 2008-03-06

DOI: 10.1159/000113714PMID: 18322402

Antiparkinsonian therapy modifications in PD patients after STN DBS: a retrospective observational analysis.

Zibetti M, Pesare M, Cinquepalmi A, Rosso M, Bergamasco B, Ducati A, Lanotte M, Lopiano L.

Parkinsonism Relat Disord · 2008-03-06

DOI: 10.1016/j.parkreldis.2007.12.009PMID: 18328768

NEURODEGENERATIVE DISEASE TREATMENT USING JAK/STAT INHIBITION

TAN JUN, FERNANDEZ FRANK, SUN NAN, SHYTLE ROLAND D, EHRHART JARED.

· 2008-03-03

COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS

CASTILLO GERARDO M, LAKE THOMAS, LARSEN DAVID, LARSEN LESLEY, LORIMER STEPHEN, NGUYEN BETH, SANDERS VIRGINIA, SNOW ALAN D, WEAVERS REX, COFFEN DAVID.

· 2008-03-03

Apraxia of eyelid opening after subthalamic deep brain stimulation may be caused by reduction of levodopa.

Umemura A, Toyoda T, Yamamoto K, Oka Y, Ishii F, Yamada K.

Parkinsonism Relat Disord · 2008-03-03

DOI: 10.1016/j.parkreldis.2007.12.008PMID: 18316231